MC2 Therapeutics is a privately held clinical stage specialty pharmaceutical company engaged in dermatology and ophthalmology.
Using our proprietary PAD™ Technology we are developing a pipeline of new topical drugs with superior real-life clinical profiles designed for optimal patient compliance. We aim to provide a unique experience for patients and an attractive benefit to value proposition for payers.
Many topical diseases are chronic and require life-long treatment why adherence is critical. It is a major problem that patients do not like to use some of the otherwise most efficacious topical therapies available. Our patient centric approach is dual – the most efficacious and safe API’s delivered in elegant formulations that patients will want to use everyday.
We are satisfied when patients using PAD™ based drugs feel free to engage with other people and be as active and social as they want during treatment.